Cannabis Stock Releases Huge News-THC Therapeutics, Inc. (THCT)

May 15, 2019 -- InvestorsHub NewsWire -- Microcap Speculators -- One challenge several upcoming cannabis stocks face is proving they are ‘for real’. Well, one stock we have been tracking, THC Therapeutics, Inc. (USOTC: THCT), just made a major announcement in this regard. THCT announced Enzo Villani was appointed a member of the company’s Board of Directors. Mr. Villani is Co-Founder of Nasdaq Global Corporate Solutions Group. Mr. Villani has raised over $500 million in funding from strategic investors, private equity, venture capital, family offices and the public markets during his over twenty-year career.

Today we are highlighting: THC Therapeutics, Inc. (USOTC: THCT), Aphria (NYSE: APHA), HEXO Corp. (AMEX: HEXO), Auxly Cannabis Group Inc. (CBWTF), and Cara Therapeutics (NASDAQ: CARA).

THC Therapeutics, Inc. (USOTC: THCT) (Market Cap: $136.195M; Share Price: $9.89) has developed a sanitizing herb dryer, The dHydronator®. Their laboratory-proven product is specifically designed for drying and sanitizing freshly harvested cannabis and herbs. THCT’s product has been tested by two independent laboratories. The testing covered over 6 strains and 9 independent tests to confirm the findings. Over the 9 tests and 6 strains, there was a 4% average increase of THC-A*.

THCT’s dHydronator can reduce moisture content of cannabis to 10% in only 10-14 hours. This is the same reason Aurora just signed a deal with EnWave. THCT received patent protection on 20 claims from the US patent office in March ’19 and will be using their patented designs to carve out their piece of the legal cannabis market expected to reach $146.4 billion by 2025. The company has received full patent protection for the dHydronator®. Start your research today on THCT.

________

Aphria Inc. (NYSE: APHA) (Market Cap: $1.74B; Share Price: $6.95) shares fell after the Canadian cannabis company reported fiscal third-quarter results. It posted a C$108.2 million ($81.1 million) loss for its fiscal third quarter, or 43 cents a share, after a profit of C$12.9 million, or 8 cents a share, in the same period a year ago. Revenue climbed to C$73.6 million from C$10.3 million in the first full quarter of Canadian legal cannabis. But the company sold less cannabis than a year ago—kilograms sold fell to 2,636.5 from 3,408.9, while the average retail selling price for medical cannabis increased to C$8.03 per gram from C$7.51, primarily because of higher oil sales.

In April, it announced that the previously announced take-over bid (the "Offer") by Green Growth Brands Inc. ("GGB") has failed to meet the statutory minimum tender condition and has now expired and is terminated. As previously announced on April 15, 2019, the company entered into a definitive agreement with GGB to accelerate the expiry date of the Offer to April 25, 2019, as well as to terminate certain arrangements with GA Opportunities Corp. ("GAOC") for consideration of $89.0 million payable on future dates as set out in the April 15th press release. The Offer is now expired and terminated and no longer open to any Aphria shareholder to tender their shares. Accordingly, GGB will not be taking up any securities that may have been tendered to the Offer. GGB will promptly return to the securityholder any Aphria shares tendered and not withdrawn during the period from the commencement of the Offer up to the expiry time of the Offer.

________

HEXO Corp (AMEX: HEXO) (Market Cap: $1.454B; Share Price: $6.85) and Newstrike Brands Ltd. ("Newstrike") (TSX-V: HIP) had announced in March that they had entered into a definitive arrangement agreement (the "Arrangement Agreement") under which HEXO will acquire all of Newstrike’s issued and outstanding common shares in an all-share transaction valued at approximately $263 million. The Transaction gives HEXO the capacity to produce approximately 150,000 kg of high-quality cannabis annually. The Transaction also provides HEXO access to four cutting-edge production campuses totalling close to 1.8 million sq. ft. of near-term cultivation space and diversified growing and production techniques. This is in addition to HEXO’s 579,000 sq. ft. facility for a manufacturing and product development centre of excellence in Belleville, Ontario. HEXO Corp has its headquarters in Gatineau Canada, and it produces and sells most of its cannabis products in the country.

The Brantford, Ontario-based Newstrike Brands were granted a cultivation license on 16 December 2016, and the company expects its harvest to be about 42,000 kg of cannabis. Although the company has not been around for long compared to HEXO, it has high capacity for cannabis production. HEXO recently announced that it had completed the first harvest in its 1 million sq. ft. expansion, marking an important execution milestone in the company's continuous growth.

HEXO Corp., through its subsidiary, HEXO Operations Inc., produces, markets, and sells cannabis in Canada. The company offers dried cannabis under the Time of Day and H2 lines; Elixir, a cannabis oil sublingual mist product line; and Decarb, an activated fine-milled cannabis powder product. It provides its products under the HEXO and Hydropothecary brand names. The company serves medical and adult-use markets. As one of the largest licensed cannabis companies in Canada, HEXO Corp operates with 1.8 million sq. ft of facilities in Ontario and Quebec and a foothold in Greece to establish a Eurozone processing, production and distribution center.

_________

Auxly Cannabis Group Inc. (CBWTF) (Market Cap: $363.713M; Share Price: $0.60) released its fourth quarter and full year 2018 financial results in March 2019. These filings and additional information regarding Auxly are available for review on SEDAR. For the year ended December 31, 2018, Auxly recognized $747,000 of research revenues from the recently completed acquisition of KGK in the third quarter of 2018. Auxly realized a gross loss of $188,000 in 2018 comprised of revenues less KGK expenses of $1,078,000 in support of third-party research contracts.

On April 8, it announced that its wholly-owned subsidiary, Robinsons Cannabis Inc. ("Robinsons"), has been granted standard cultivation and processing licenses by Health Canada pursuant to the Cannabis Act and Cannabis Regulations. The licenses give Robinsons the ability to begin cultivation at its fully constructed 27,700 square-foot facility in Kentville, Nova Scotia, which was purpose-built to produce high-quality cannabis.

Auxly Cannabis Group Inc. operates as a cannabis streaming company. It provides funding for cannabis production; and holds contractual rights and minority equity interest relating to the operation of cannabis facilities. The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. Auxly Cannabis Group Inc. was incorporated in 1987 and is headquartered in Vancouver, Canada.

________

Cara Therapeutics, Inc. (NASDAQ: CARA) (Market Cap: $724.672M; Share Price: $18.23), a clinical-stage biopharmaceutical company, has a comprehensive report issued by Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies. Cara Therapeutics focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors.

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body's peripheral nervous system, as well as certain immune cells.

________

Signed by

Priyanka Goel, CFA

Legal Disclaimer:

This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal Consulting has agreed to a three-month term consulting agreement with THCT dated 2/14/18. The agreement calls for 50,000 restricted shares of THCT per month. This agreement has been amended to $20,000 per month, and 55,000 shares per month and extended for twelve months ending 3/18/2020. All payments were made directly by THC Therapeutics, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. THCT was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.

http://www.regalconsultingllc.com/full legal disclaimer/

Full Legal Disclaimer Click Here.

Contact Information:

Company Name: ACR Communication LLC.

Contact Person: Media Manager

Email: info@microcapspeculators.com

Phone: 1-702-720-6310

Country: United States

SOURCE: Microcap Speculators

Aphria (NASDAQ:APHA)
Historical Stock Chart
From Mar 2024 to Apr 2024